Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies ...

More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.

The US Food and Drug Administration (FDA) has rejected Biogen’s high-dose Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA). The agency chose to decline the antisense ...

Biogen recently reported fourth-quarter and full-year 2025 results showing quarterly sales of US$521.2 million and revenue of US$2.28 billion, but a quarterly net loss of US$48.9 million contrasted ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Turning Tides, a DTC campaign from Biogen and Supernus, uses storm-at-sea imagery and a streaming-first media plan to connect with new parents and spotlight the first oral treatment for postpartum ...

If Novo Nordisk A/S’s wildly popular weight-loss drug succeeds in a highly anticipated trial for Alzheimer’s disease, Biogen Inc.’s Chief Executive Officer Chris Viehbacher doesn’t see it as a ...

Following Biogen’s recent failure of Aduhelm and a CEO resignation on the horizon, the drugmaker’s new Alzheimer’s drug candidate showed promising results in a phase 3 trial with a 27 percent slower ...

Biogen and Alkermes won approval Oct. 30 for their new multiple sclerosis drug, Vumerity, according to The Boston Globe. Vumerity is an oral drug designed to treat relapsing forms of MS, a chronic ...